Amgen carries one of the higher scores (3.9, B+) among healthcare megacaps, with growth (A-), profitability (A), and momentum (A-) all grading well — suggesting its drug pipeline (including obesity treatments) is defending results effectively despite biosimilar competition pressure.

A 2.27% dividend yield is solid too, making it a reasonably balanced healthcare pick for investors seeking both income and growth. Valuation (C, ~27x P/E) isn't especially demanding relative to those strong factor grades.